JP2022506719A5 - - Google Patents

Info

Publication number
JP2022506719A5
JP2022506719A5 JP2021524282A JP2021524282A JP2022506719A5 JP 2022506719 A5 JP2022506719 A5 JP 2022506719A5 JP 2021524282 A JP2021524282 A JP 2021524282A JP 2021524282 A JP2021524282 A JP 2021524282A JP 2022506719 A5 JP2022506719 A5 JP 2022506719A5
Authority
JP
Japan
Prior art keywords
seq
antibody
occupied
cdr
antibody according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021524282A
Other languages
English (en)
Japanese (ja)
Other versions
JP7623699B2 (ja
JP2022506719A (ja
Filing date
Publication date
Priority claimed from PCT/US2018/059895 external-priority patent/WO2020096608A1/en
Application filed filed Critical
Priority claimed from PCT/US2019/060616 external-priority patent/WO2020097561A1/en
Publication of JP2022506719A publication Critical patent/JP2022506719A/ja
Publication of JP2022506719A5 publication Critical patent/JP2022506719A5/ja
Priority to JP2025003312A priority Critical patent/JP2025063136A/ja
Application granted granted Critical
Publication of JP7623699B2 publication Critical patent/JP7623699B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021524282A 2018-11-08 2019-11-08 タウ認識抗体 Active JP7623699B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025003312A JP2025063136A (ja) 2018-11-08 2025-01-09 タウ認識抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
USPCT/US2018/059895 2018-11-08
PCT/US2018/059895 WO2020096608A1 (en) 2018-11-08 2018-11-08 Antibodies recognizing tau
US201862758421P 2018-11-09 2018-11-09
US62/758,421 2018-11-09
PCT/US2019/060616 WO2020097561A1 (en) 2018-11-08 2019-11-08 Antibodies recognizing tau

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025003312A Division JP2025063136A (ja) 2018-11-08 2025-01-09 タウ認識抗体

Publications (3)

Publication Number Publication Date
JP2022506719A JP2022506719A (ja) 2022-01-17
JP2022506719A5 true JP2022506719A5 (cg-RX-API-DMAC7.html) 2022-11-15
JP7623699B2 JP7623699B2 (ja) 2025-01-29

Family

ID=70610738

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021524282A Active JP7623699B2 (ja) 2018-11-08 2019-11-08 タウ認識抗体
JP2025003312A Pending JP2025063136A (ja) 2018-11-08 2025-01-09 タウ認識抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025003312A Pending JP2025063136A (ja) 2018-11-08 2025-01-09 タウ認識抗体

Country Status (18)

Country Link
US (1) US20220153821A1 (cg-RX-API-DMAC7.html)
EP (1) EP3877410A4 (cg-RX-API-DMAC7.html)
JP (2) JP7623699B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210090184A (cg-RX-API-DMAC7.html)
CN (2) CN113454112B (cg-RX-API-DMAC7.html)
AU (1) AU2019377595B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008624A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021001158A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007370A2 (cg-RX-API-DMAC7.html)
CU (1) CU24781B1 (cg-RX-API-DMAC7.html)
IL (1) IL283049A (cg-RX-API-DMAC7.html)
JO (1) JOP20210098A1 (cg-RX-API-DMAC7.html)
MX (2) MX2021005411A (cg-RX-API-DMAC7.html)
PE (1) PE20211777A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551048A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202104549TA (cg-RX-API-DMAC7.html)
UA (1) UA129124C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020097561A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
SG11202104549TA (en) * 2018-11-08 2021-05-28 Prothena Biosciences Ltd Antibodies recognizing tau
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別tau之抗體
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
JP2025535203A (ja) 2022-09-15 2025-10-23 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
CN115724967A (zh) * 2022-09-21 2023-03-03 天津鸿宇泰生物科技有限公司 一种识别Tau蛋白N端区域的单克隆抗体及其应用
CN116925217B (zh) * 2023-09-14 2024-03-08 北京凯祥弘康生物科技有限公司 针对Tau蛋白的抗体
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2026102093A1 (en) 2024-11-07 2026-05-15 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
MY128897A (en) 1999-02-05 2007-02-28 Samsung Electronics Co Ltd Image texture retrieving method and apparatus thereof
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
EP1470146B8 (en) 2001-12-28 2007-09-12 Amgen Fremont Inc. Antibodies against the muc18 antigen
DE50308030D1 (de) 2002-11-29 2007-10-04 Boehringer Ingelheim Pharma Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
EP1820022B1 (en) 2004-11-10 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
PL2099823T5 (pl) 2006-12-01 2023-02-20 Seagen Inc. Wariant środków wiążących cel i jego zastosowania
PL2583978T3 (pl) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
EP2522730A1 (en) 2007-03-02 2012-11-14 Boehringer Ingelheim Pharma GmbH & Co. KG Improvement of protein production
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
LT2627672T (lt) * 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
EP3275461A1 (en) * 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
CA2869438C (en) * 2012-04-05 2021-08-17 Ac Immune S.A. Humanized tau antibody
JP6284548B2 (ja) * 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. ヒト抗タウ抗体
EP3221349B1 (en) * 2014-11-19 2020-11-04 Axon Neuroscience SE Humanized tau antibodies in alzheimer's disease
NZ775762A (en) * 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
EP3380622A4 (en) 2015-11-23 2019-08-07 Sangamo Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODIFYING IMMUNITY
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
US10570196B2 (en) * 2016-07-20 2020-02-25 Anahit Ghochikyan Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
SG11202104549TA (en) * 2018-11-08 2021-05-28 Prothena Biosciences Ltd Antibodies recognizing tau
TWI859197B (zh) * 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別tau之抗體

Similar Documents

Publication Publication Date Title
IL262726B1 (en) Antibodies recognizing tau
JP2025029046A5 (cg-RX-API-DMAC7.html)
JP6993992B2 (ja) 抗pd-1抗体、その産生方法及びその使用方法
JP2020078319A (ja) Cd269(bcma)に対する抗体
JP2019525724A5 (cg-RX-API-DMAC7.html)
JP2016512551A5 (cg-RX-API-DMAC7.html)
JP2018510617A5 (cg-RX-API-DMAC7.html)
JP2022524588A5 (cg-RX-API-DMAC7.html)
JP6666257B2 (ja) プロアポトーシス活性を有するgd2−o−アセチル化ガングリオシドに対する抗体
JP2019525728A5 (cg-RX-API-DMAC7.html)
JP2020513791A5 (cg-RX-API-DMAC7.html)
JP2010532764A5 (cg-RX-API-DMAC7.html)
JP2025063136A (ja) タウ認識抗体
RU2011150916A (ru) Антитела против vegf и их применения
US20160207996A1 (en) Antibodies to complex targets
JP2013056885A5 (cg-RX-API-DMAC7.html)
JP2012515746A (ja) 抗cd160モノクローナル抗体及びその使用
JP2020536532A5 (cg-RX-API-DMAC7.html)
RU2019140602A (ru) АНТИ-GARP-TGF-β-АНТИТЕЛА
JP2021094022A5 (cg-RX-API-DMAC7.html)
JP2012525829A5 (cg-RX-API-DMAC7.html)
JP2018509889A5 (cg-RX-API-DMAC7.html)
CA2420231A1 (en) Antibodies to human il-1.beta.
JP2018506277A5 (cg-RX-API-DMAC7.html)
JP2010524435A5 (cg-RX-API-DMAC7.html)